MBF Therapeutics is an immunotherapeutics company focused on animal applications of its innovative T-Max™ immunotherapeutic DNA vaccine platform. In addition, there are significant translational opportunities in human health. Our T-Max platform addresses longstanding shortcomings of traditional viral vaccine technologies based primarily on killed/inactivated (KWV) whole virus or modified live/attenuated virus vaccines (MLV/AV). Killed virus vaccines have been fairly safe but not efficacious, while MLV vaccine must replicate to generate reasonable efficacy and therefore have significant safety issues for the vaccinated animal and also the herd because of chronic carriers and viral shedding. MBFT will create safe and efficacious vaccines focused on respiratory viral diseases that cause significant negative economic and social impacts. Specifically Porcine Reproductive and Respiratory Syndrome (PRRS) considered the most economically significant disease of worldwide swine production; and African Swine Fever (ASF), a highly fatal and reportable disease that has caused billions of dollars lost due to death/cull of millions of pigs and disrupted markets and trade throughout Asia, Europe, Africa and now threatens the US with an estimated cost impact of 50 billion dollars in lost trade and containment costs. T-Max Plasmid DNA Vaccine Platform MBFT’s T-Max™ DNA vaccine platform is a proprietary process from discovery to commercialization of protective vaccines that identifies clinically relevant pathogen antigens and delivers them in proprietary formulations to stimulate durable and potent T cell immune responses. Four components differentiate the platform: 1. Novel antigen selection process to identify multiple clinically relevant antigens to create cross-protective ”universal” vaccines; 2. Cloning into proprietary plasmids containing a non-antibiotic selection system; 3. One or more immunomodulators that stimulate a strong innate immune response; and 4. CaptaVa